Moderna, AstraZeneca Present Positive Data from Phase 2 Study Assessing mRNA Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Moderna, AstraZeneca Present Positive Data from Phase 2 Study Assessing mRNA Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery

Moderna presented positive data from the AstraZeneca-led EPICCURE study evaluating the use of AZD8601, an mRNA therapeutic encoding for vascular endothelial growth factor-A (VEGF-A), in patients undergoing coronary artery bypass grafting (CABG). The trial met the primary endpoint of safety and tolerability and showed numerical trends in three exploratory efficacy endpoints. These data were presented today at the American Heart Association’s Scientific Sessions 2021 annual meeting.

EPICCURE is a randomized, placebo-controlled, double-blind, multicenter, 6-month, Phase 2a clinical trial. The trial enrolled 11 patients with stable coronary artery disease and moderately decreased left ventricular ejection fraction (LVEF) undergoing CABG surgery. The patients were randomized to a series of epicardial injections in ischemic but viable myocardium at the time of surgery with AZD8601 or placebo. Patients were followed for 6 months. 

There were no deaths or treatment-related serious adverse events, and no infections were observed related to the treatment of AZD8601. Numerical trends were observed in endpoints in the heart failure efficacy domains compared with...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee